Neophyr (Nitric Oxide)

Nitric Oxide, the active ingredient in Neophyr, is a gaseous signaling molecule presented as an inhalation therapy for pulmonary vascular conditions. It is used to selectively dilate the pulmonary circulation and improve oxygenation in specific respiratory disorders. GNH USA supplies Neophyr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neophyr is employed in clinical settings that target pulmonary vascular dysfunction and related respiratory challenges. - Persistent Pulmonary Hypertension of the Newborn (PPHN): improves oxygenation by selective pulmonary vasodilation. - Acute Respiratory Distress Syndrome (ARDS): reduces pulmonary artery pressure and enhances ventilation‑perfusion matching. - Right Ventricular Failure associated with pulmonary hypertension: lowers pulmonary vascular resistance to support right‑heart function.

Neophyr may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate discomfort often reported during therapy. - Hypotension: transient drop in systemic blood pressure. - Dizziness: sensation of light‑headedness. - Nausea: occasional upset stomach. - Flushing: warm sensation and reddening of skin. - Cough: irritation of the airway during inhalation.

Serious or Rare Side Effects: - Methemoglobinemia: elevated methemoglobin levels impairing oxygen delivery. - Rebound pulmonary hypertension: sudden rise in pulmonary pressure after abrupt discontinuation. - Severe hypotension: marked systemic blood pressure decline requiring intervention. - Bleeding: increased risk when combined with anticoagulants. - Pulmonary edema: fluid accumulation in the lungs. - Infection: potential contamination of delivery system leading to respiratory infection.

When using Neophyr, clinicians should observe several safety measures to minimize risk. - Monitoring of blood methemoglobin levels: regular checks are recommended during therapy. - Use in patients with respiratory infections: assess risk of bacterial growth in the delivery system. - Concomitant use with phosphodiesterase‑5 inhibitors: may enhance hypotensive effect. - Pregnancy and breastfeeding: safety not established; use only if benefit outweighs potential risk. - Store at ambient temperature: keep container sealed, protect from moisture and direct sunlight.

Neophyr can interact with other medications, requiring careful assessment of potential additive effects.

Major Interactions (Avoid): - Other pulmonary vasodilators (e.g., inhaled prostacyclin): additive hypotension risk. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): may cause severe systemic hypotension. - Methylene blue: antagonizes nitric oxide activity, reducing efficacy.

Moderate Interactions (Monitor Closely): - General anesthetics: may potentiate vasodilatory response. - Anticoagulants: monitor for increased bleeding tendency. - Bronchodilators: may increase cough or airway irritation.